Key Findings on GLP-1 Use in MS

GLP-1 receptor agonists (e.g., Ozempic, Wegovy) show potential in multiple sclerosis (MS) as potential neuroprotective, anti-inflammatory, and weight-loss agents. Preclinical studies show reduced neuroinflammation, and small studies indicate safety for MS patients, though they are not yet proven as primary disease-modifying therapies (DMTs). National Institutes of Health (.gov) +3

Key Findings on GLP-1 Use in MS:

• Neuroprotective Potential: Preclinical studies suggest that, in addition to managing weight, GLP-1 agents may help reduce MS-related inflammation and support neuronal integrity.
• Safety and Tolerability: A study published in PubMed noted that early data suggests these drugs are well-tolerated by people with MS and do not appear to exacerbate disease activity.
• Weight Management Impact: Obesity is linked to higher MS disability. GLP-1s have been shown to help MS patients achieve weight loss, potentially improving mobility and energy levels.
• Limited Evidence for Disease Modification: As of 2026, research indicates that while they are safe for weight loss, GLP-1s do not show significant protection against disability or disease progression.
• Clinical Studies: Studies are ongoing, such as the ClinicalTrials.gov (NCT07207148) trial, which aims to examine the effect of GLP-1s on disability progression, notes the National Multiple Sclerosis Society. 

Considerations:

• Side Effects: Potential side effects include nausea, diarrhea, and constipation, which could worsen pre-existing MS-related bowel issues, explains the National Institutes of Health.

• Not a Replacement for DMTs: These drugs should not replace approved MS disease-modifying therapies, warns Can Do MS. 

Always consult with a neurologist regarding the use of GLP-1 agonists.